arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Monday 5 sept 2022

Monday 05 Sep

07:30

Registration

08:50

New and Hot

Chairs Hein Sprong, Netherlands (RIVM) and Joppe Hovius, Netherlands (Amsterdam UMC)

08:50

Short introduction chairs

09:00

What's new in Lyme diagnostics?

John Branda, USA (Invited speaker, Harvard University)

This presentation will highlight recent developments and promising research avenues in the field of diagnostic testing for Lyme borreliosis.

John Branda

John Branda

Associate Professor of Pathology

09:20

New directions of therapy of tick-borne encephalitis

Daniel Ruzek, Czech Republic (Invited speaker, Czech Academy of Sciences)

Tick-borne encephalitis is a potentially fatal neuroinfection in humans. Currently, no specific drugs are approved for the treatment of TBE. This presentation will review recent developments in specific antiviral therapy and immunotherapy for TBE. The mechanisms of action and the advantages or limitations of new antiviral drugs and immunotherapy for TBE treatment will also be discussed.

Daniel Ruzek

Daniel Ruzek

Head of the department of Virology

09:40

Borrelia burgdorferi PlzA is a c-di-GMP dependent DNA binding protein

Nerina Jusufovic, United States (University Of Kentucky)

10:00

Autoimmunity to synovial fibroblast-derived extracellular matrix proteins in patients with post-infectious Lyme arthritis

Allen Steere, United States (Harvard Medical School, Massachusetts General Hospital)

10:20

Break and Coffee

10:50

Epidemiology

Chair: Paul Mead, USA (Centers for Disease Control and Prevention)

10:50

Short introduction chair

11:00

Why are we so bothered by ticks? Or the surveillance pyramid of European Lyme borreliosis from a Dutch perspective.

Kees van den Wijngaard, Netherlands (Invited speaker, RIVM)

Lyme borreliosis (LB) and other tick-borne diseases get great attention, and many people are anxious for tick bites and their possible consequences. Tick bites and to a less extent EM are quite common, whereas disseminated LB and persisting symptoms attributed to LB are relatively rare. Nevertheless these severe manifestations have the highest burden, and thus probably bother us the most. A major contribution in prevention may be a future Lyme vaccine. Until then, we will have to deal with the burden of LB, including long-term symptoms attributed to LB.

Kees van den Wijngaard

Kees van den Wijngaard

Senior Researcher at the Epidemiology Department at RIVM, Centre for Infectious Disease Control

11:30

Epidemiology and costs of Lyme borreliosis infections in Germany – a retrospective claims data analysis

Christine Hagemann, Germany (Pfizer Pharma Gmbh)

11:50

Utility of Commercial Insurance Claims to define the Incidence of Lyme disease During Pregnancy

Alison Hinckley, United States (U.S. Centers For Disease Control And Prevention)

Poster Pitches

12:10

Click below to view the program of the poster pitches

12.10 – Duration of symptoms among clinician-diagnosed Lyme disease patients in the Northeast and Upper Midwest, United States
Sara Niesobecki, United States (Connecticut Emerging Infections Program/Yale School Of Public Health)

12.13 – Persistent Borrelia burgdorferi sensu lato infection after antibiotic treatment: a systematic overview and appraisal of the current evidence from experimental animal models
Amber Vrijlandt, Netherlands (Amsterdam University Medical Centers)

12.16 – Transcriptome mapping of B. burgdorferi reveals RNA regulators
Philip Adams, United States (National Institutes of Health)

12.19 – Investigating small and medium-sized mammals to identify potential reservoirs of Borrelia miyamotoi in the North Central U.S.A.
Seungeun Han, Sweden (National Veterinary Institute)

12.22 – Development of a multiplex peptide ELISA for serological identification of Borrelia burgdorferi sensu stricto, B. garinii and B. afzelii in human sera
Antonio Foddai, United Kingdom (University Of Aberdeen)

12.25 – Designing a cocktail vaccine against Lyme borreliosis combining tick- and Borrelia-derived antigens
Alexis Burnham, Netherlands (Amsterdam University Medical Center)

12:30

Lunch & Posters

14:30

Clinical Aspects

Chair: Franc Strle, Slovenia (University of Ljubljana)

14:30

Short introduction chair

14:40

Lyme disease; from acute disease to persisting symptoms

Gary Wormser, USA (Invited speaker, New York Medical College)

More information will follow.

Picturegwormser0505

Gary Wormser

15:10

Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis

Sergio Hernández, United States (New York State Department Of Health)

15:30

Tick-borne encephalitis in the Åland Islands 2006-2020: incidence and clinical characteristics since implementation of mass vaccination.

Marika Nordberg, Finland (Åland Central Hospital)

15:50

Treatment of Erythema Migrans With Doxycycline for 7 Days Versus 14 Days: a Noninferiority Randomized Open-Label Study

Daša Stupica, Slovenia (UMC Ljubljana)

16:10

Break and Coffee

16:30

Young & Wild: Early carreer researchers’ presentations

Chairs: Allen Steere, USA (Harvard University) & Franc Strle, Slovenia (University of Ljubljana)

16:30

Short introduction chairs

16:40

Chromosome segregation in polyploid Borrelia burgdorferi spirochetes is orchestrated by a novel centromere-binding protein, ParZ

Constantin Takacs, United States (Stanford University and HHMI)

17:00

Multidisciplinary Management of Suspected Lyme Borreliosis: Clinical Features of 569 Patients, and Factors Associated with Recovery at 12 Months, a Prospective Cohort Study

Alice Raffetin, France (Ch Villeneuve-saint-georges)

17:20

Changes in the human skin immune landscape facilitate tick-borne pathogen transmission

Johanna Strobl, Austria (Medical University Of Vienna)

17:40

Closing